Liya Ma

发表

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

Jie Jin, Chao Hu, Weilai Xu, 2018, Journal of Cancer Research and Clinical Oncology.

The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts

Yingwan Luo, Yanling Ren, Xinping Zhou, 2018, Leukemia & lymphoma.

Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes

Jie Jin, P. Lin, Yingwan Luo, 2021, Cancer medicine.

Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein.

Weiwei Zhu, W. Qian, Liya Ma, 2015, Oncology letters.

Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial

Jie Jin, Yue-min Kuang, Yanling Ren, 2020, Hematological oncology.

Clinical and biological characteristics of acute myeloid leukemia with 20–29% blasts: a retrospective single-center study

Jie Jin, P. Lin, Yingwan Luo, 2018, Leukemia & lymphoma.

Analysis of clinical and molecular features of MDS patients with complex karyotype in China.

Jie Jin, P. Lin, Yingwan Luo, 2019, Blood cells, molecules & diseases.

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation

Yue-min Kuang, Liya Ma, H. Tong, 2022, Frontiers in Oncology.

CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain

Jianfeng Zhou, Lei Zhao, Jia Wei, 2020, Frontiers in Oncology.

Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes.

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2020, American journal of cancer research.

Clinical Characteristics and Outcomes of Tuberculosis Infection in Adult Patients with MDS

Yingwan Luo, Shuanghong Zhu, Haiyang Yang, 2020 .

Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study

Jie Jin, Xinping Zhou, C. Mei, 2021, Leukemia & lymphoma.

Loss of expression of LyGDI (ARHGDIB), a rho GDP‐dissociation inhibitor, in Hodgkin lymphoma *

W. Klapper, R. Siebert, M. Szczepanowski, 2007, British journal of haematology.

All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex

Xiaozhen Liu, P. Lin, Yingwan Luo, 2022, British Journal of Cancer.

Identification of a de novo mutation of the FOXG1 gene and comprehensive analysis for molecular factors in Chinese FOXG1-related encephalopathies

Guanting Lu, Liya Ma, Jin Wu, 2022, Frontiers in Molecular Neuroscience.

Successful treatment of Candida tropicalis osteomyelitis with Micafungin in a leukemia patient

Xinping Zhou, Liya Ma, H. Tong, 2016, IDCases.

Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2022, Journal of Cancer Research and Clinical Oncology.

Mutation status and burden can improve prognostic prediction of patients with lower‐risk myelodysplastic syndromes

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2019, Cancer science.

Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting

Jie Jin, Fangjing Shi, P. Lin, 2019, Leukemia & lymphoma.

Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.

Jie Jin, Yingwan Luo, Chao Hu, 2019, Blood cells, molecules & diseases.

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone

Jie Jin, W. Qian, P. Lin, 2017, Journal of Cancer Research and Clinical Oncology.

Nursing Countermeasures of Continuous Renal Replacement Treatment in End-Stage Renal Disease with Refractory Hypotension in the Context of Smart Health

Liya Ma, Hongwei Sun, Jianling Guo, 2022, Computational and mathematical methods in medicine.

The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes

Jie Jin, Xiaomei Yan, M. Azam, 2018, Haematologica.

Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases

Jian Huang, Jie Jin, W. Qian, 2016, Frontiers of Medicine.

Empirical polymyxin B therapy in febrile neutropenic patients with hematological diseases: A prospective, multicenter, observational clinical study.

Jianping Shen, Chao Hu, Xinping Zhou, 2023, The Journal of infection.

Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients

Y. Li, Min Yang, Jian Huang, 2015, PloS one.

Venetoclax plus ‘2 + 5’ modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single‐centre retrospective analysis

Min Yang, Yungui Wang, Liya Ma, 2022, British Journal of Haematology.

Real‐world data of chronic myelomonocytic leukemia: A chinese single‐center retrospective study

Jie Jin, P. Lin, Yingwan Luo, 2021, Cancer medicine.

15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study

Yingwan Luo, Haiyang Yang, Xinping Zhou, 2022, Hematological oncology.

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

Jie Jin, Z. Zhuang, P. Lin, 2018, Journal of Cancer Research and Clinical Oncology.

Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study.

Xinping Zhou, Liya Ma, H. Tong, 2024, European journal of cancer.

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Jian Huang, Jie Jin, Chao Hu, 2016, Leukemia & lymphoma.

RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells

Yingwan Luo, Shuanghong Zhu, Xinping Zhou, 2024, Science advances.

Co‐mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome

Yingwan Luo, Xinping Zhou, C. Mei, 2022, Hematological oncology.